<code id='B387BA7F5F'></code><style id='B387BA7F5F'></style>
    • <acronym id='B387BA7F5F'></acronym>
      <center id='B387BA7F5F'><center id='B387BA7F5F'><tfoot id='B387BA7F5F'></tfoot></center><abbr id='B387BA7F5F'><dir id='B387BA7F5F'><tfoot id='B387BA7F5F'></tfoot><noframes id='B387BA7F5F'>

    • <optgroup id='B387BA7F5F'><strike id='B387BA7F5F'><sup id='B387BA7F5F'></sup></strike><code id='B387BA7F5F'></code></optgroup>
        1. <b id='B387BA7F5F'><label id='B387BA7F5F'><select id='B387BA7F5F'><dt id='B387BA7F5F'><span id='B387BA7F5F'></span></dt></select></label></b><u id='B387BA7F5F'></u>
          <i id='B387BA7F5F'><strike id='B387BA7F5F'><tt id='B387BA7F5F'><pre id='B387BA7F5F'></pre></tt></strike></i>

          entertainment

          entertainment

          author:entertainment    Page View:723
          Adobe

          For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight over who held patent rights to CRISPR-Cas9, the revolutionary genome editing tool.

          Editas Medicine, the winner of that battle in the U.S., will now cash in.

          advertisement

          Vertex Pharmaceuticals and Editas announced Wednesday that Vertex will pay Editas $50 million, along with a series of annual payments through 2034, in exchange for rights to use CRISPR-Cas9 in Casgevy, the sickle cell therapy approved last week.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Stem cell treatment guidelines are released by FDA
          Stem cell treatment guidelines are released by FDA

          HumanembryonicstemcellsAnnieCavanagh/WellcomeImagesTheFoodandDrugAdministrationonThursdayunveiledase

          read more
          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more

          Physician assistants need a new name. Here's what it should be

          AdobeI’mstandingoveranoperatingtable,excisingaskincancerfromtheforeheadofanelderlygentlemanwhilesoft